Manufacturer of Controlled Substances, Notice of Registration, Halo Pharmaceutical, Inc., 75672 [2012-30774]
Download as PDF
<![CDATA[
75672
Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices
Drug
Schedule
Oxymorphone (9652) ...................
Racemethorphan (9732) ..............
Racemorphan (9733) ...................
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers for use as reference
standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Chemtos, LLC, to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Chemtos, LLC, to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
The company plans to manufacture
Hydromorphone HCL for sale to other
manufacturers, and for the manufacture
of other controlled substance dosage
units for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of Halo
Pharmaceutical, Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Halo Pharmaceutical, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–30774 Filed 12–20–12; 8:45 am]
[FR Doc. 2012–30781 Filed 12–20–12; 8:45 am]
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
BILLING CODE 4410–09–P
FOR FURTHER INFORMATION CONTACT:
BILLING CODE 4410–09–P
Arts Advisory Panel Meeting
DEPARTMENT OF JUSTICE
National Endowment for the
Arts, National Foundation on the Arts
and Humanities.
ACTION: Notice of Meeting.
AGENCY:
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Registration,
Halo Pharmaceutical, Inc.
mstockstill on DSK4VPTVN1PROD with
Schedule
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone
and is not for commercial distribution.
VerDate Mar<15>2010
18:28 Dec 20, 2012
Jkt 229001
Pursuant to Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), as amended, notice is
hereby given that seven meetings of the
Arts Advisory Panel to the National
Council on the Arts will be held at the
Nancy Hanks Center, 1100 Pennsylvania
Avenue NW., Washington, DC 20506
(unless otherwise noted) as follows
(ending times are approximate):
International (application review): By
teleoconference. This meeting will be
closed.
Dates: January 8, 2013; 1:00 p.m. to
2:00 p.m. e.s.t.
Folk & Traditional Arts (application
review): In room 716. This meeting will
be closed.
Dates: January 11, 2013; 9:00 a.m. to
5:30 p.m. e.s.t.
SUMMARY:
By Notice dated July 30, 2012, and
published in the Federal Register on
August 7, 2012, 77 FR 47114, Halo
Pharmaceutical, Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
State & Regional (review of state
partnership agreements): In Room 716.
This meeting will be open.
Dates: January 16–17, 2013; From 9:00
a.m. to 5:00 p.m. e.s.t. on January 16th
and from 9:00 a.m. to 3:30 p.m. e.s.t. on
January 17th.
Music (review of nominations): 3
Columbus Circle, 12th Floor, New York,
NY 10019 and by teleconference. This
meeting will be closed.
Dates: January 15, 2013, from 9:00
a.m. to 10:15 a.m. e.s.t.
State & Regional (review of regional
partnership agreements): By
teleconference. This meeting will be
open.
Dates: January 30, 2013; From 3:00
p.m. to 4:00 p.m. e.s.t.
Folk & Traditional Arts (review of
nominations): In room 716. This
meeting will be closed.
Dates: January 29–February 1, 2013;
from 9:00 a.m. to 5:30 p.m. e.s.t. on
January 29th–31st and from 9:00 a.m. to
1:00 p.m. e.s.t. on February 1st.
Research (application review): In
Room 627. This meeting will be closed.
Dates: January 29–30, 2013; From 9:00
a.m. to 5:30 p.m. e.s.t. on January 29th
and from 9:00 a.m. to 5:00 p.m. e.s.t. on
January 30th.
PO 00000
Frm 00067
Fmt 4703
Sfmt 9990
Further information with reference to
these meetings can be obtained from Ms.
Kathy Plowitz-Worden, Office of
Guidelines & Panel Operations, National
Endowment for the Arts, Washington,
DC 20506; plowitzk@arts.gov or call
202/682–5691.
The
closed portions of meetings are for the
purpose of Panel review, discussion,
evaluation, and recommendations on
financial assistance under the National
Foundation on the Arts and the
Humanities Act of 1965, as amended,
including information given in
confidence to the agency. In accordance
with the determination of the Chairman
of February 15, 2012, these sessions will
be closed to the public pursuant to
subsection (c)(6) of section 552b of Title
5, United States Code.
SUPPLEMENTARY INFORMATION:
Dated: December 18, 2012.
Kathy Plowitz-Worden,
Panel Coordinator, National Endowment for
the Arts.
[FR Doc. 2012–30759 Filed 12–20–12; 8:45 am]
BILLING CODE 7537–01–P
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 77, Number 246 (Friday, December 21, 2012)]
[Notices]
[Page 75672]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30774]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Registration,
Halo Pharmaceutical, Inc.
By Notice dated July 30, 2012, and published in the Federal
Register on August 7, 2012, 77 FR 47114, Halo Pharmaceutical, Inc., 30
North Jefferson Road, Whippany, New Jersey 07981, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
Dihydromorphine is an intermediate in the manufacture of
Hydromorphone and is not for commercial distribution. The company plans
to manufacture Hydromorphone HCL for sale to other manufacturers, and
for the manufacture of other controlled substance dosage units for
distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Halo Pharmaceutical, Inc., to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Halo Pharmaceutical, Inc., to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-30774 Filed 12-20-12; 8:45 am]
BILLING CODE 4410-09-P
